Recently published results of the phase 3 clinical trial for Covaxin shows that it is 93% effective in preventing serious disease.
Recently published results of the phase 3 clinical trial for Covaxin shows that it is 93% effective in preventing serious disease.
Dr. Shankar Musunuri, Chairman, CEO and Co-Founder of Ocugen, speaks to The American Bazaar.
The American Bazaar is a publication of American Bazaar, Inc., based in Germantown, MD.